Protective Effect Of Eicosapentaenoic Acid Research Articles

Impaired Filterability of Erythrocytes from Patients with Chronic Hepatitis C and Effects of Eicosapentaenoic Acid on the Filterability

Although erythrocyte filterability plays a key role in microcirculation, it is unknown whether the filterability of erythrocytes from patients with chronic hepatitis C (CH-C) is impaired. This study aimed to investigate erythrocyte filterability in CH-C patients in relation to medical treatment. The mean erythrocyte filterability (%) for all 24 patients with CH-C (69.2 +/- 10.8%) was significantly lower than that for 5 normal controls (80.5 +/- 1.7%, P < 0.03). In 8 patients, the combination therapy of ribavirin (RBV) and interferon improved liver function but caused anemia. The filterability after treatment (57.8 +/- 12.8%) was lower than that before treatment (70.8 +/- 9.7%, P < 0.05). Decreased filterability showed no correlation with the mean corpuscular volume or mean corpuscular Hb concentration during treatment, suggesting that the decrease in filterability mainly arises from changes in erythrocyte membrane properties. We investigated the protective effects of eicosapentaenoic acid (EPA) on the RBV-induced anemia. Filterability in 7 responders was markedly improved from 68.4 +/- 4.6% to 77.4 +/- 2.4% (P < 0.001), but not in 3 nonresponders. In the responders, the progression of anemia was restrained. In conclusion, we found an obvious impairment of the filterability of erythrocytes from CH-C patients, further impairment of the filterability induced by oxidative membrane damage caused by RBV leading to hemolytic anemia, and amelioration of the filterability caused by the antioxidative effects of EPA.

Analysis of Interleukin-1β-induced Cell Signaling Activation in Rat Hippocampus following Exposure to Gamma Irradiation: PROTECTIVE EFFECT OF EICOSAPENTAENOIC ACID

Among the many reported effects of irradiation in cells is activation of the stress-activated protein kinase, c-Jun N-terminal kinase (JNK), which has been shown to result in apoptotic cell death. The trigger that leads to JNK activation has not been identified, although, in rat hippocampus at least, irradiation-induced apoptosis has been coupled with increased accumulation of reactive oxygen species (ROS). Significantly, irradiation-induced changes in hippocampus are abrogated by treatment of rats with the polyunsaturated fatty acid, eicosapentaenoic acid (EPA). A close coupling between ROS accumulation and concentration of the pro-inflammatory cytokine, interleukin-1 beta (IL-1 beta) in hippocampus has been reported, and the evidence suggests that IL-1 beta may be responsible for the enhanced ROS production. Here we set out to assess the possibility that whole body gamma-irradiation increases IL-1 beta concentration in hippocampus and to investigate the consequences of such a change. We present evidence that reveals that the irradiation-induced increase in IL-1 beta concentration in hippocampus is accompanied by increased expression of IL-1 type I receptor and IL-1 accessory protein and increased activation of IL-1 receptor-activated kinase. These changes, which were coupled with increased activation of JNK and evidence of apoptotic cell death, were absent in hippocampus of rats that received EPA treatment. Significantly, EPA treatment enhanced hippocampal IL-10 concentration that was inversely correlated with IL-1 beta concentration. The data are consistent with the idea that EPA exerts anti-inflammatory and neuroprotective effects in the central nervous system.

Eicosapentaenoic acid protects endothelial cell function injured by hypoxia/reoxygenation.

Eicosapentaenoic acid (EPA) may protect against atherosclerosis by improving lipid metabolism and modulating vascular cell function. Ischemia/ reperfusion injury is one risk factor for atherosclerosis. We investigated if EPA could improve hypoxia/reoxygenation (H/R)-induced endothelial cell dysfunction of gap junctional intercellular communication (GJIC). GJIC in human umbilical vascular endothelial cells (HUVECs) was measured using a photobleaching technique. Results demonstrated that H (24h)/R 2h) induced a GJIC reduction in HUVECs; however, it was inhibited by EPA pretreatment. H/R produced reactive oxygen species, but it was not affected by EPA, and it contributed little to GJIC dysfunction. By contrast, tyrosine kinase activated by H/R was inhibited by EPA pretreatment, and tyrosine kinase inhibitors also abolished H/R-induced GJIC reduction. The protective effects of EPA on the H/R-induced GJIC reduction was also observed in cells treated with tyrosine phosphatase inhibitor. These data indicate the EPA improves H/R-induced endothelial dysfunction through inhibition of tyrosine kinase activation, and it could lead to prevention of progression and/or initiation of atherosclerosis.

Pretreatment with eicosapentaenoic acid prevented hypoxia/reoxygenation-induced abnormality in endothelial gap junctional intercellular communication through inhibiting the tyrosine kinase activity

Eicosapentaenoic acid (EPA) may protect against atherosclerotic disease, and modulation of endothelium function is one possible mechanism. Hypoxia/reoxygenation (H/R) is a potential risk factor for the pathogenesis of atherosclerosis, and it causes endothelial dysfunction. To evaluate whether EPA may improve the endothelial dysfunction under the condition of H/R, we examined endothelial gap junctional intercellular communication (GJIC), which is said to be important for the endothelium to maintain its normal function. The results indicate that H/R induced a temporal reduction in GJIC after 2 h of reoxygenation in cultured human umbilical vein endothelial cells (HUVEC). This reduction in GJIC was not observed in cells pretreated with 3 mg/ml EPA for 2 days. The results of immunofluorescence show that 2 h reoxygenation caused an increased production of tyrosine-phosphorylated proteins, which was inhibited by EPA pretreatment. Immunoprecipitation demonstrated that tyrosine residues of connexin 43 (Cx43), an important gap junctional protein in HUVEC, were phosphorylated by H/R. However, pretreatment with EPA significantly suppressed this increased phosphorylation. The protective effect of EPA on the reduction in GJIC was also observed in cells treated with 1.5 mM vanadate, a tyrosine phosphatase inhibitor. These data suggest that EPA may ameliorate the H/R-induced GJIC abnormality via inhibition of the tyrosine kinase activation.

Effect of Amiodarone on Release of Cytokines from Mouse Alveolar Macrophages Pretreated with Eicosapentaenoic Acid

I studied the effect of amiodarone, a cationic amphiphilic drug, on the cytokine release and protein kinase C (PKC) activity of mouse alveolar macrophages. In addition, I examined the relationship between amiodarone and eicosapentaenoic acid (EPA) with respect to the cytokine release. The decrease in cell number caused by amiodarone was depressed by pretreatment of the macrophages with EPA for 2 days and co-treatment for 1 day. These changes reflected the potency of EPA to protect against the cell injury elicited by amiodarone. As regards to the cytokine release, amiodarone caused an increase in interleukin (IL)-1α, IL-1β and tumor necrosis factor (TNF)α release from macrophages. As EPA suppressed this increase in cytokine levels, I considered that the protective effect of EPA may be extended to the acute release of cytokines. PKC activity was increased by amiodarone, and this increase was depressed by EPA. These changes were well-related to the results on cytokine levels in this study, indicating that amiodarone firstly activated PKC, leading to the stimulation of release of cytokines and that pretreatment with EPA prevented these effects. I conclude that mouse alveolar macrophages treated with amiodarone show activated release of cytokines and that EPA depresses these increases, thereby demonstrating EPA’s antiinflammatory effect and protective action against injury of alveolar macrophages.

Protective effect of eicosapentaenoic acid on ouabain toxicity in neonatal rat cardiac myocytes.

Isolated neonatal cardiac myocytes have been utilized as a model for the study of cardiac arrhythmogenic factors. The myocytes respond to the toxic effects of a potent cardiac glycoside, ouabain at 0.1 mM, by an increase in their spontaneous beating rate and a reduction in amplitude of contractions resulting within minutes in a lethal state of contracture. Incubating the isolated myocytes for 3-5 days in culture medium enriched with 5 microM arachidonic acid [20:4 (n-6)] had no effect on the development of lethal contracture after subsequent exposure to 0.1 mM ouabain. By contrast, incubating the myocytes for 3-5 days with 5 microM eicosapentaenoic acid [20:5 (n-3)] completely prevented the toxic effects of ouabain at 0.1 mM. There were no measurable differences in the degree to which ouabain inhibited Na,K-ATPase activity by comparing the control with the arachidonic acid- or the eicosapentaenoic acid-enriched myocytes. No differences in bumetanide-inhibitable 86Rb flux were observed between the three preparations. However, measurements with fura-2 of cytosolic free calcium levels indicated that control and arachidonic acid-enriched myocytes developed toxic cytosolic calcium concentrations of 845 +/- 29 and 757 +/- 64 nM, respectively, on exposure to 0.1 mM ouabain, whereas in eicosapentaenoic acid-enriched myocytes, physiologic calcium levels (214 +/- 29 nM) were preserved. Incubating the myocytes with eicosapentaenoic acid (5 microM) for 3-5 days resulted in a small reduction of arachidonic acid and a small but significant increase of eicosapentaenoic acid in membrane phospholipids of the myocytes.